EUVIMEDEUVIMED entdecken
Crossref

Study on the homeostasis mechanism of in vivo degradation of PCL microsphere fillers

Shuang Wu iD, Qi Guo, Rongling Liu, Zhisheng Yan, Ranran Tang, Shuo Pang iD, Wenjie Chen, Tun Yuan iD

Journal of Biomaterials Applications · 08.07.2026

DOI: 10.1177/08853282261469759 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomaterials Applications, online erschienen am 08.07.2026. Verfasst von Shuang Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, China. Die Arbeit nennt 37 Literaturangaben. Gefördert von: the National key research and development programs of China, China NMPA Research on performance and safety evaluation of innovative biomaterial medical devices, Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycaprolactone (PCL) has been widely applied in the fields of medical aesthetics and clinical filling due to its excellent biocompatibility, controllable degradability, and favorable mechanical properties. However, the high crystallinity and hydrophobicity result in a longer degradation period, making it more suitable for long-term and sustained filling treatments. Yet it is difficult to observe the degradation endpoint in a short period of time, which poses a challenge for the safety and efficacy evaluation of the product before its market launch. At present, the differences in in vivo behavior among various PCL microspheres and their clinical implications remain incompletely understood. In this study, a subcutaneous implantation model in rabbits was employed to investigate the in vivo degradation patterns of two types of PCL microsphere fillers and the material–tissue interactions contributing to the establishment of bodily homeostasis. The results demonstrated that PCL microsphere fillers achieve a homeostasis of safety at 12 months through a sequential process involving “surface erosion–cellular involvement–collagen encapsulation.” Furthermore, they maintain a homeostasis of efficacy for at least 30 months via a collagen remodeling strategy characterized by “initial reinforcement, subsequent shaping, and eventual equilibration,” thereby forming a predictable dynamic filler construct. These findings provide a mechanistic basis for individualized clinical application and quality evaluation.

Schlagwörter

Stichwörter der Autor:innen

collagen regenerationfiller constructhomeostasisintradermal degradationpolycaprolactone

Autor:innen und Institutionen

  • National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, China.
  • College of Biomedical Engineering, Sichuan University, Chengdu, China.
  • Sichuan Testing Centre for Biomaterials and Medical Devices, Chengdu, China.
  • Chengdu Zhongxing Meiyuan Biotechnology Co., Ltd, Chengdu, China.
  • Xihong Biopharma, Jiangsu, China.

ORCID-Profile: Shuang Wu, Shuo Pang, Tun Yuan

Förderung

  • the National key research and development programs of China
  • China NMPA Research on performance and safety evaluation of innovative biomaterial medical devices
  • Beijing Natural Science Foundation

Zitieren

APA

Wu, S., Guo, Q., Liu, R., Yan, Z., Tang, R., Pang, S., Chen, W., & Yuan, T. (2026). Study on the homeostasis mechanism of in vivo degradation of PCL microsphere fillers. Journal of Biomaterials Applications. https://doi.org/10.1177/08853282261469759

Vancouver

Wu S, Guo Q, Liu R, Yan Z, Tang R, Pang S, et al. Study on the homeostasis mechanism of in vivo degradation of PCL microsphere fillers. Journal of Biomaterials Applications. 2026. doi:10.1177/08853282261469759

BibTeX
@article{Wu2026,
  author = {Wu, Shuang and Guo, Qi and Liu, Rongling and Yan, Zhisheng and Tang, Ranran and Pang, Shuo and Chen, Wenjie and Yuan, Tun},
  title = {Study on the homeostasis mechanism of in vivo degradation of PCL microsphere fillers},
  journal = {Journal of Biomaterials Applications},
  year = {2026},
  doi = {10.1177/08853282261469759}
}
Kostenlos starten →